ARTHROPLASTY
Edoxaban has similar efficacy to enoxaparin for thromboprophylaxis after THA
J Arthroplasty. 2014 Dec;29(12):2439-46.264 patients scheduled for total hip arthroplasty were randomized to one of three groups: a group which received 15mg edoxaban daily, a group which received 30mg edoxaban daily, or a group which received 20mg of enoxaparin sodium twice daily. This was done to determine the safety, efficacy, and optimal dosage regimen of edoxaban as compared to enoxaparin in patients undergoing total hip arthroplasty. Factors such as the incidence of thromboembolic events, bleeding, and adverse drug reactions were evaluated over a 14 day postoperative period. The results demonstrated that edoxaban is a safe and efficacious alternative to enoxaparin sodium, and that a 30mg daily dose of edoxaban is appropriate.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
